Generate Biomedicines (NASDAQ:GENB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Generate Biomedicines (NASDAQ:GENB) from a sell rating to a hold rating in a report published on Saturday morning.

Other analysts also recently issued reports about the stock. HC Wainwright increased their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Morgan Stanley boosted their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Trading Up 2.1%

Shares of GENB stock opened at $13.68 on Friday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $18.18. The firm has a market capitalization of $1.75 billion and a price-to-earnings ratio of -12.79. The stock’s 50 day simple moving average is $14.36.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.